<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813577</url>
  </required_header>
  <id_info>
    <org_study_id>CL0025-01</org_study_id>
    <nct_id>NCT02813577</nct_id>
  </id_info>
  <brief_title>Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)</brief_title>
  <acronym>CONFIRM</acronym>
  <official_title>A Prospective, Multicenter, Single Arm, Post-Approval Study of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The post approval study will enroll US female patients presenting with claudication or
      ischemic rest pain and an angiographically significant lesion in the superficial femoral or
      popliteal artery. Subjects are treated per Instructions For Use (IFU) with the Lutonix®
      Catheter. Subjects will have a Duplex Ultrasound (DUS) and clinical follow-up through two (2)
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Lutonix® 035 Drug Coated Balloon PTA Catheter (Lutonix® Catheter) has been approved by
      the Food and Drug Administration (P130024) for percutaneous transluminal angioplasty, after
      appropriate vessel preparation of de novo, restenotic, or in-stent restenotic lesions up to
      300 mm in length in native superficial femoral or popliteal arteries with reference vessel
      diameters of 4-7 mm. The purpose of this post-approval study is to assess the safety and
      effectiveness of the Lutonix® Catheter in the US female population. This study will enroll
      approximately 165 female patients at a minimum of 10 US centers and a maximum of 25.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA allowed other data to be leveraged to meet the study requirements
  </why_stopped>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Actual">February 18, 2019</completion_date>
  <primary_completion_date type="Actual">February 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure</measure>
    <time_frame>12 months post index procedure</time_frame>
    <description>Index limb amputation includes above or below the ankle amputations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.</measure>
    <time_frame>12 months post index procedure</time_frame>
    <description>Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.</measure>
    <time_frame>30 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Vascular Complications at 30 Days Post Index Procedure</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths (All Causes) at 30 Days Post Index Procedure</measure>
    <time_frame>30 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure</measure>
    <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure</measure>
    <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure</measure>
    <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure</measure>
    <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline</measure>
    <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure</measure>
    <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline</measure>
    <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Femoral Artery Stenosis</condition>
  <condition>Popliteal Artery Stenosis</condition>
  <condition>Femoral Artery Occlusion</condition>
  <condition>Popliteal Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Lutonix® 035 Drug Coated Balloon PTA Catheter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix® 035 Drug Coated Balloon PTA Catheter</intervention_name>
    <description>Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
    <arm_group_label>Lutonix® 035 Drug Coated Balloon PTA Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Criteria

          1. Non-pregnant female ≥18 years of age;

          2. Rutherford Clinical Category 2-4;

          3. Patient is willing to provide informed consent, is geographically stable, comply with
             the required follow up visits and testing schedule;

             Angiographic Criteria

          4. De novo or restenotic lesion(s) in native superficial femoral or popliteal arteries;

          5. Lesion ≥70% stenosis by visual estimate;

          6. Target reference vessel diameter of 4-7 mm;

          7. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by
             angiography; (Treatment of target lesion acceptable after successful treatment of
             inflow artery lesions. Successful inflow artery treatment is defined as attainment of
             residual diameter stenosis ≤30% without death or major vascular complication.)

          8. At least one patent native outflow artery to the ankle, free from significant (≥50%)
             stenosis as confirmed by angiography after successful vessel preparation;

          9. Successful antegrade wire crossing and vessel preparation (may include pre-dilatation)
             of the target lesion. Successful vessel preparation is defined by residual stenosis
             ≤30% without any major vascular complications;

         10. No other prior vascular interventions within 2 weeks before and/or planned 30 days
             after the protocol treatment except for remote common femoral patch angioplasty
             separated by at least 2 cm from the lesion(s).

        Exclusion Criteria

          1. Life expectancy of &lt;2 years;

          2. Subject is currently participating in an investigational drug or device study, or
             previously enrolled in this study. Enrollment in another investigational drug or
             device study during the follow up period is not allowed;

          3. History of stroke within 3 months;

          4. History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of index
             procedure;

          5. Renal failure or chronic kidney disease with serum creatinine ≥2.5 mg/L within 30 days
             of index procedure or treated with dialysis;

          6. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target
             vessel.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Metzger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellmont CVA Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Access Solutions</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bardpv.com/?portfolio=lutonix-035</url>
    <description>Lutonix® 035 Drug Coated Balloon PTA Catheter Instructions For Use</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <results_first_submitted>April 10, 2020</results_first_submitted>
  <results_first_submitted_qc>April 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Legs</keyword>
  <keyword>Drug Coated Angioplasty Balloon</keyword>
  <keyword>Experimental</keyword>
  <keyword>Standard Angioplasty Balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02813577/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
          <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study was terminated and only some results at 1 month follow up are available.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
          <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>≥18 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure</title>
        <description>Index limb amputation includes above or below the ankle amputations.</description>
        <time_frame>12 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure</title>
          <description>Index limb amputation includes above or below the ankle amputations.</description>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.</title>
        <description>Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.</description>
        <time_frame>12 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.</title>
          <description>Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.</description>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.</title>
        <time_frame>30 days post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Major Vascular Complications at 30 Days Post Index Procedure</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Major Vascular Complications at 30 Days Post Index Procedure</title>
          <units>Complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths (All Causes) at 30 Days Post Index Procedure</title>
        <time_frame>30 days post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths (All Causes) at 30 Days Post Index Procedure</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure</title>
        <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
        <population>Study terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure</title>
          <population>Study terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure</title>
        <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure</title>
        <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure</title>
        <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.</title>
        <time_frame>1, 6, 12 and 24 months</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline</title>
        <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure</title>
        <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline</title>
        <time_frame>1, 6, 12 and 24 months post index procedure</time_frame>
        <population>Study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
            <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline</title>
          <population>Study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At 1 month post-index procedure.</time_frame>
      <desc>Only the following type of endpoint related adverse events were reported:
Events leading to death
Target limb reintervention
Target limb amputation
Any event deemed to be device- or procedure-related
Major vascular complication within 30 days of the index procedure
Any event involving the target limb that requires treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Lutonix® 035 Drug Coated Balloon PTA Catheter</title>
          <description>This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to PI publication of site results, sponsor requires publication of multi-centers results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Lovas</name_or_title>
      <organization>Becton Dickinson</organization>
      <phone>763-445-2385</phone>
      <email>anna.lovas@bd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

